United Therapeutics

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Trade United Therapeutics 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About UTHR

United Therapeutics Corp. is a biotechnology company, which engages in the development and commercialization of products for patients with chronic and life-threatening conditions. Its products include Adcirca, Orenitram, Remodulin, TYVASO, and Unituxin. 

CEO
Martine A. Rothblatt
CEOMartine A. Rothblatt
Employees
1,400
Employees1,400
Headquarters
Silver Spring, Maryland
HeadquartersSilver Spring, Maryland
Founded
1996
Founded1996
Employees
1,400
Employees1,400

UTHR Key Statistics

Market cap
23.13B
Market cap23.13B
Price-Earnings ratio
20.55
Price-Earnings ratio20.55
Dividend yield
Dividend yield
Average volume
473.49K
Average volume473.49K
High today
$560.97
High today$560.97
Low today
$544.49
Low today$544.49
Open price
$552.30
Open price$552.30
Volume
472.64K
Volume472.64K
52 Week high
$609.35
52 Week high$609.35
52 Week low
$272.12
52 Week low$272.12

Stock Snapshot

With a market cap of 23.13B, United Therapeutics(UTHR) trades at $544.62. The stock has a price-to-earnings ratio of 20.55.

On 2026-06-01, United Therapeutics(UTHR) stock moved within a range of $544.49 to $560.97. With shares now at $544.62, the stock is trading +0.0% above its intraday low and -2.9% below the session's peak.

Trading activity shows a volume of 472.64K, compared to an average daily volume of 473.49K.

Over the past 52 weeks, United Therapeutics(UTHR) stock has traded between a high of $609.35 and a low of $272.12.

Over the past 52 weeks, United Therapeutics(UTHR) stock has traded between a high of $609.35 and a low of $272.12.

UTHR News

Investing.com 3d
United Therapeutics CEO Rothblatt exercises, sells $5.37m in stock - Investing.com

...

United Therapeutics CEO Rothblatt exercises, sells $5.37m in stock - Investing.com
TipRanks 4d
PHINDER Trial Update: How Earlier Pulmonary Hypertension Screening Could Shape United Therapeutics’ Market

United Therapeutics Corp. (UTHR) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from a...

TipRanks 5d
United Therapeutics Advances High-Risk, High-Reward Xenokidney Trial for ESRD

United Therapeutics Corp. (UTHR) announced an update on their ongoing clinical study. Unlock trusted, data-backed investing tools with TipRanks Premium, from a...

Analyst ratings

81%

of 16 ratings
Buy
81.3%
Hold
18.8%
Sell
0%

People also own

Based on the portfolios of people who own UTHR. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.